Post by
ryehigh2014 on Nov 01, 2016 9:50pm
Valeant Salix
Anyone have any opinions on this? This is HUGE for VRX if they seal the deal. Basically unwinding.
Curious however:
- Salix has $900MM Expected EBITDA for 2017
- Its IBS drug Xifafen has competition
- Its portfolio is also subject to regulatory risk and political risk
So if Takeda sees value despite this than the pharma sector obviously has value. Thoughts on Salix anyone?
Comment by
MegaBear on Nov 01, 2016 11:37pm
This post has been removed in accordance with Community Policy
Comment by
MustardTiger88 on Nov 02, 2016 1:53am
I'm confused as to why this is good news for Valeant. Didn't they buy Salix last year for almost $15 billion?